ACRO urged the FDA to include contract research organizations directly in the agency’s AI trial pilot for early-phase studies. The group said CROs should participate as primary stakeholders rather than appearing only through sponsors, arguing they have line-of-sight into global clinical trial execution and can help regulators design oversight without slowing innovation.